Visual Outcome After Vitrectomy With Subretinal tPA Injection
NCT ID: NCT05196139
Last Updated: 2022-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
96 participants
OBSERVATIONAL
2021-04-01
2021-08-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
NCT05514925
Optic Nerve and Retinal Functions With Bevacizumab
NCT01361828
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
NCT01350323
VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents
NCT01655589
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
retrospective study
vitrectomy performed in case of submacular bleeding
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with submacular bleeding
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Stalmans, PhD
Role: PRINCIPAL_INVESTIGATOR
UZ Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
65203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.